- Senate passes Drug Quality and Security Act
- FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga
- Reports: ESI may start 'price war' over new hepatitis C drugs
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
PRINCETON, N.J. — A panel of experts at the Food and Drug Administration has recommended approval for an experimental biotech drug under development by Bristol-Myers Squibb and AstraZeneca for a group of rare metabolic disorders.
The drug makers said the FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11-1 to recommend that the agency approve metreleptin for treating children and adults with generalized lipodystrophy, also known as LD. LD disorders cause severe metabolic abnormalities and significant morbidity and death. The FDA is not required to follow the votes of advisory committees when considering whether to approve a drug, but it usually does.
However, the committee did not vote in favor of recommending the drug for patients with metabolic disorders associated with partial LD, though the companies said they would continue to push for approval for that usage.